A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients Using Alemtuzumab, and Rituximab.
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2016
At a glance
- Drugs Alemtuzumab (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 05 Aug 2016 Status changed from recruiting to discontinued according to results published in the American Journal of Hematology.
- 24 Oct 2012 New source identified and integrated (Mayo Clinic).
- 11 Jul 2012 Planned End Date changed from 1 Feb 2012 to 1 Dec 2017 as reported by ClinicalTrials.gov.